S. Louise Phanstiel bought $495k of MYGN
director at MYRIAD GENETICS INC. 104,507 shares at an average of $4.73, traded Feb 25, 2026, filed Feb 27, 2026.
Score components
- +15RoleDirector
- +18Trade size$495k at market
- +10Relative to holdingsHoldings up 59%
- +8Price context59% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -7.2%, 3m -13.9%, 6m -31.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001471518-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 25, 2026 | POpen-market purchase Common Stock | +6,100 | $4.74 | $29k | 183,544 | Feb 27, 2026 |
| Feb 26, 2026 | POpen-market purchase Common Stock | +50,407 | $4.80 | $242k | 233,951 | Feb 27, 2026 |
| Feb 27, 2026 | POpen-market purchase Common Stock | +48,000 | $4.66 | $224k | 281,951 | Feb 27, 2026 |
Related signals
Other insiders at MYRIAD GENETICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | MYRIAD GENETICS INC | Rashmi Kumar director | $67k 15,000 shares | -8% | |
| 41Moderate | MYGNbuy MYRIAD GENETICS INC | Paul Bisaro director | $28k 7,500 shares | +8% | |
| 56Moderate | MYRIAD GENETICS INC | Samraat S. Raha President and CEO | $200k 40,000 shares | +9% | |
| 20Weak | MYRIAD GENETICS INC | Paul J Diaz President and CEO | $344k 15,000 shares | -2% | |
| 36Weak | MYRIAD GENETICS INC | Paul J Diaz President and CEO | $401k 15,000 shares | -2% | |
| 37Weak | MYRIAD GENETICS INC | Dale Muzzey Chief Scientific Officer | $55k 2,100 shares | -2% | |
| 43Moderate | MYRIAD GENETICS INC | Heinrich Dreismann director | $271k 10,000 shares | -8% | |
| 55Moderate | MYRIAD GENETICS INC | Colleen F Reitan director | $1.3M 46,012 shares | -52% | |
| 49Moderate | MYRIAD GENETICS INC | Margaret Ancona SVP, Chief of Staff | $321k 11,538 shares | -13% | |
| 15Weak | MYRIAD GENETICS INC | Rashmi Kumar director | $210k 7,500 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.